NORCROSS,SpectRx has been awarded a patent for technology used in a device for non-invasive cervical cancer that is currently undergoing FDA clinical trials.

SpectRx has developed a device that identifies cancers and precancers by analyzing light reflected from the cervix. A tissue sample is not required.

SpectRx has formed a subsidiary, Guided Therapeutics, to commercialize the device.

Guided Therapeutics: